Elevated osteopontin levels in patients with peripheral arterial disease

Angiology

Volumn 60, Issue 1, 2009, Pages 42-45

  Koshikawa, Megumi ^a   Aizawa, Kazunori ^a   Kasai, Hiroki ^a   Izawa, Atsushi ^a   Tomita, Takeshi ^a   Kumazaki, Setsuo ^a   Tsutsui, Hiroshi ^a   Koyama, Jun ^a   Shimodaira, Shigetaka ^a   Takahashi, Masafumi ^a   Ikeda, Uichi ^a  

^a SHINSHU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytokine; Osteopontin; Peripheral arterial disease

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; OSTEOPONTIN; OSTEOPROTEGERIN;

AGED; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERABILITY; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANKLE; BIOLOGICAL MARKERS; BLOOD PRESSURE; BRACHIAL ARTERY; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPONTIN; OSTEOPROTEGERIN; PERIPHERAL VASCULAR DISEASES; TREATMENT OUTCOME; UP-REGULATION;

EID: 59149099846     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319708314250     Document Type: Article

References (33)

1. Lai C., Seshadri V., Huang K., et al. An osteopontin-NADPH oxidase signaling cascade promotes pro-matrix metalloproteinase 9 activation in aortic mesenchymal cells. Circ Res. 2006 ; 98: 1479-1489.
2. Minoretti P., Falcone C., Calcagnino M., et al. Prognostic significance of plasma osteopontin levels in patients with chronic stable angina. Eur Heart J. 2006 ; 27: 802-807.
3. Isoda K., Nishikawa K., Kamezawa Y., et al. Osteopontin plays an important role in the development of medial thickening and neointimal formation. Circ Res. 2002 ; 91: 77-82.
4. Bruemmer D., Collins AR, Noh G., et al. Angiotensin IIaccelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest. 2003 ; 112: 1318-1331.
5. Denhardt DT, Noda M., O'Regan AW, Pavlin D., Berman JS Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest. 2001 ; 107: 1055-1061.
6. Steitz SA, Speer MY, McKee MD, et al. Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol. 2002 ; 161: 2035-2046.
7. Giachelli CM, Base N., Almeida M., Denhardt DT, Alpers CE, Schwartz SM Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest. 1993 ; 92: 1686-1696.
8. Panda D., Kundu GC, Lee BI, et al. Potential roles of osteopontin and αvβ3 integrin in the development of coronary artery restenosis after angioplasty. Proc Natl Acad Sci U S A. 1997 ; 94: 9308-9313.
9. Golledge J., McCann M., Mangan S., Lam A., Karan M. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke. 2004 ; 35: 1636-1641.
10. Zhang J., Fu M., Myles D., et al. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett. 2002 ; 521: 180-184.
11. deBlois D., Lombardi DM, Su EJ, Clowes AW, Schwartz SM, Giachelli CM Angiotensin II induction of osteopontin expression and DNA replication in rat arteries. Hypertension. 1996 ; 28: 1055-1063.
12. Kiechl S., Schett G., Wenning G., et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004 ; 109: 2175-2180.
13. Soejima H., Irie A., Fukunaga T., et al. Elevated plasma osteopontin levels were associated with osteopontin expression of CD4+ T cells in patients with unstable angina. Circ J. 2006 ; 70: 851-856.
14. Kato R., Momiyama Y., Ohmori R., et al. High plasma levels of osteopontin in patients with restenosis after percutaneous coronary intervention. Arterioscler Thromb Vasc Biol. 2006 ; 26: e1-2.
15. Kurata M., Okura T., Watanabe S., Fukuoka T., Higaki J. Osteopontin and carotid atherosclerosis in patients with essential hypertension. Clin Sci (Lond). 2006 ; 111: 319-324.
16. Golledge J., Muller J., Shephard N., et al. Association between osteopontin and human abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 2007 ; 27: 655-660.
17. Jono S., Ikari Y., Shioi A., et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation. 2002 ; 106: 1192-1194.
18. Schoppet M., Sattler AM, Schaefer JR, Herzum M., Maisch B., Hofbauer LC Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab. 2003 ; 88: 1024-1028.
19. Ziegler S., Kudlacek S., Luger A., Minar E. Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis. 2005 ; 182: 175-180.
20. Pennisi P., Signorelli SS, Riccobene S., et al. Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. Osteoporos Int. 2004 ; 15: 389-395.
21. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003 ; 26 (suppl 1). S5 - S20.
22. Takemoto M., Yokote K., Nishimura M., et al. Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis. Arterioscler Thromb Vasc Biol. 2000 ; 20: 624-628.
23. Ohmori R., Momiyama Y., Taniguchi H., et al. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis. 2003 ; 170: 333-337.
24. Hirota S., Imakita M., Kohri K., et al. Expression of osteopontin messenger RNA by macrophages in atherosclerotic plaques: a possible association with calcification. Am J Pathol. 1993 ; 143: 1003-1008.
25. Fitzpatrick LA, Severson A., Edwards WD, Ingram RT Diffuse calcification in human coronary arteries: association of osteopontin with atherosclerosis. J Clin Invest. 1994 ; 94: 1597-1604.
26. Bini A., Mann KG, Kudryk BJ, Schoen FJ Noncollagenous bone matrix proteins, calcification, and thrombosis in carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol. 1999 ; 19: 1852-1861.
27. Singh K., Balligand JL, Fischer TA, Smith TW, Kelly RA Glucocorticoids increase osteopontin expression in cardiac myocytes and microvascular endothelial cells: Role in regulation of inducible nitric oxide synthase. J Biol Chem. 1995 ; 270: 28471-28478.
28. Isoda K., Kamezawa Y., Ayaori M., Kusuhara M., Tada N., Ohsuzu F. Osteopontin transgenic mice fed a high-cholesterol diet develop early fatty-streak lesions. Circulation. 2003 ; 107: 679-681.
29. Matsui Y., Rittling SR, Okamoto H., et al. Osteopontin deficiency attenuates atherosclerosis in female apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2003 ; 23: 1029-1034.
30. Liaw L., Lombardi DM, Almeida MM, Schwartz SM, deBlois D., Giachelli CM Neutralizing antibodies directed against osteopontin inhibit rat carotid neointimal thickening after endothelial denudation. Arterioscler Thromb Vasc Biol. 1997 ; 17: 188-193.
31. Nitta K., Akiba T., Uchida K., et al. The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis. 2003 ; 42: 303-309.
32. Moran CS, McCann M., Karan M., Norman P., Ketheesan N., Golledge J. Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation. 2005 ; 111: 3119-3125.
33. Avignon A., Sultan A., Piot C., et al. Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients. Diabetes Care. 2007 ; 30: 2934-2939.